LifeVantage revels in 'activation era' with debut of GLP-1 system

Nutrigenomics company LifeVantage is turning down food noise by turning up GLP-1 production. The company just launched its MindBody GLP-1 System, a dual product offering that includes MB Core and MB Enhance, which work together to activate natural GLP-1 production.

The system works in tandem to activate the body's natural production of GLP-1, a hormone that plays a crucial role in regulating appetite and metabolism.

As explained by LifeVantage, MB Core directly stimulates the specialized L-cells in the gut to produce more GLP-1, while MB Enhance provides the resistant fibers and essential nutrients the gut microbiome needs to further boost those GLP-1 levels. By harnessing the body's mechanisms, this science-backed approach aims to support sustainable weight management without the need for pharmaceutical interventions.

“We came up with the MB Core, which actively activates the cell directly, and then the MB enhance, which is our resistant fiber and nutritional food for the microbiome," said Christina Beer, senior research scientist at LifeVantage. "They indirectly activate GLP-1 production at the same time, and they work synergistically. We've tested them individually, and we've tested them together as a system, and this system far outperforms the individual.

“So we're turning on production of GLP-1 in the L-cells of the colon, and then we're increasing the effect of that production by feeding our microbiome with the resistant fibers and starches that it needs," added Tyler Horton, senior director, global product marketing at LifeVantage. "It forms butyrate, which is the preferred fuel of those L cells, so we're boosting that production." 

A 12-week clinical trial on the system showed that participants experienced an average 140% increase in GLP-1 levels, leading to a steady weight loss of one to two pounds per week, with some individuals losing up to 25 pounds. Notably, participants did not lose any muscle mass—a common issue with weight loss drugs.

Beer and Horton said they are excited about their science-backed approach and hinted at future product expansions to 'activate' more health benefits.